The Technical AnalystExchange: TWO Sector: Healthcare Industry: Biotechnology
Oneness Biotech Co., Ltd. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.19% TWD156.00
America/New_York / 7 mai 2024 @ 01:30
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 70 883 mill |
| EPS: | -3.30 |
| P/E: | -47.27 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 454.38 mill |
| Avg Daily Volume: | 2.16 mill |
| RATING 2024-05-06 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -47.27 | sector: PE 34.77 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.81x |
| Company: PE -47.27 | industry: PE 58.06 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
TWD-11.26 (-107.22%) TWD-167.26 |
| Date: 2024-05-06 |
| Expected Trading Range (DAY) |
|---|
|
TWD 150.91 - 161.09 ( +/- 3.26%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | TWD156.00 (-2.19% ) |
| Volume | 1.315 mill |
| Avg. Vol. | 2.16 mill |
| % of Avg. Vol | 60.75 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 4743.TWO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
4743.TWO
Oneness Biotech Co., Ltd engages in the research and development of new drugs, and sale of pharmaceutical and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis and systemic sclerosis; FB825, which is in Phase II clinical trial for treating atopic dermatitis, allergic diseases, and asthma; and FB918, a human monoclonal antibody, which is in pre-clinical stage for the treatment of allergic asthma. In addition, the company engages in the management of agriculture cultivation and trading business; and sale of agricultural products. The company was incorporated in 2008 and is headquartered in Taipei City, Taiwan.